# Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study

> **NCT03798743** · PHASE2 · COMPLETED · sponsor: **Hunan Province Tumor Hospital** · enrollment: 30 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab Combined With Docetaxel

## Key facts

- **NCT ID:** NCT03798743
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-03-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798743, "Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03798743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*